Azari F, Meijer R, Kennedy G, Hanna A, Chang A, Nadeem B, Din A, Pèlegrin A, Framery B, Cailler F, Sullivan N, Kucharczuk J, Martin L, Vahrmeijer A, Singhal S Carcinoembryonic Antigen - Related Cell Adhesion Molecule Type 5 Receptor - Targeted Fluorescent Intraoperative Molecular Imaging Tracer for Lung Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023;6(1):e2252885. doi:10.1001/jamanetworkopen.2022.52885
Nishino H, Turner M, Amirfakhri S, Hollandsworth H, Lwin T, Hosseini M, Framery B, Cailler F, Pèlegrin A, Hoffman R, Bouvet M Proof of concept of improved fluorescence-guided surgery of colon cancer liver metastasis using color-coded imaging of a tumor-labeling fluorescent antibody and indocyanine green restricted to the adjacent liver segment. Surgery. 2022-08-01. doi:10.1016/j.surg.2022.05.029
Azari F, Kennedy G, Chang A, Bernstein E, Nadeem B, Pèlegrin A, Cailler F, Sullivan N, Kucharczuk J, Singhal S Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 5/2022. doi:10.1016/j.athoracsur.2022.05.019
Xiong H, Mancini M, Gobert M, Shen S, Furtado G, Lira S, Parkhurst C, Brengues M, Tadokoro C, Trimarchi T, Singh A, Khiabanian H, Minuzzo S, Indraccolo S, Lobry C, Aifantis I, Herranz D, Lafaille J, Maraver A Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021;11(4):1594-1608. doi:10.7150/thno.48067
Latorzeff I, Sargos P, Créhange G, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. Cancer Radiother. Feb 11, 2020. doi:10.1016/j.canrad.2019.06.018
Maria A, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, Crestani B, Guilpain P [From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations]. Rev Med Interne. Feb 08, 2020. doi:10.1016/j.revmed.2020.01.002
Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud H-A, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. Int. J. Radiat. Oncol. Biol. Phys.. Jan 17, 2020. doi:10.1016/j.ijrobp.2019.12.020
Bosma S, Vd Leij F, Vreeswijk S, de Maaker M, Wesseling J, Vd Vijver M, Scholten A, Rivera S, Bourgier C, Auzac G, Foukakis T, Lekberg T, Vd Bongard D, Loo C, Rutgers E, Bartelink H, Elkhuizen P Five-year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. Int. J. Radiat. Oncol. Biol. Phys.. Jan 24, 2020. doi:10.1016/j.ijrobp.2019.12.037
Latorzeff I, Bourgier C, Pinel B, Hennequin C, Jimenez G, Chapet O, Zasadny X [Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer]. Cancer Radiother. Sep 06, 2019. doi:10.1016/j.canrad.2019.08.004
Bourgier C, Latorzeff I, Fenoglietto P, Boisselier P, Charissoux M, Llacer C, Lemanski C, Riou O, Farcy-Jacquet M-P, Azria D [Treatment of oligometastatic or oligoprogression cancer]. Cancer Radiother. Sep 05, 2019. doi:10.1016/j.canrad.2019.07.143
Barbet J, Le Gouill S, Pèlegrin A [Radioimmunotherapy: the reasons for confidential clinical use and hope for development]. Med Sci (Paris). 2019;35(12):1062-1065. doi:10.1051/medsci/2019206
Riou O, Bourgier C, Brengues M, Bonnefoi N, Michaud H-A, Castan F, Gourgou S, Draghici R, Farcy-Jacquet M-P, Bons F, Fenoglietto P, Ozsahin M, Azria D [Predictive assays for responses of tumors and normal tissues in radiation oncology]. Cancer Radiother. Aug 23, 2019. doi:10.1016/j.canrad.2019.07.152
Larivière M, Pèlegrin A, Martineau P, Watier H [Players from the program "Investments for the Future": MAbImprove MabEx]. Med Sci (Paris). 2019;35(12):1204-1205. doi:10.1051/medsci/2019249
Larbouret C, Poul M-A, Chardès T [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]. Med Sci (Paris). 2019;35(12):1083-1091. doi:10.1051/medsci/2019216
Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Azria D [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother. Aug 20, 2019. doi:10.1016/j.canrad.2019.07.159
Bourgier C, Lemanski C, Draghici R, Castan F, Fenoglietto P, Bons F, Farcy-Jacquet M-P, Brengues M, Gourgou S, Ozsahin M, Azria D [Individual modification of the dose, volume and fractionation of breast radiotherapy]. Cancer Radiother. Aug 01, 2019. doi:10.1016/j.canrad.2019.06.004
Pèlegrin A, Gutowski M, Cailler F [Antibodies, tools of choice for fluorescence-guided surgery]. Med Sci (Paris). 2019;35(12):1066-1071. doi:10.1051/medsci/2019207
Pèlegrin A, Beck A, Watier H [A word from the coordinators]. Med Sci (Paris). 2019;35(12):923. doi:10.1051/medsci/2019245
Prunaretty J, Boisselier P, Riou O, Simeon S, Bedos L, Azria D, Fenoglietto P Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison. Rep Pract Oncol Radiother. 2019;24(1):97-104. doi:10.1016/j.rpor.2018.11.003
Framery B, Gutowski M, Dumas K, Evrard A, Muller N, Dubois V, Quinonero J, Scherninski F, Pèlegrin A, Cailler F Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicol Rep. 2019;6. doi:10.1016/j.toxrep.2019.04.011
Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, Coles C, Cutuli B, Falcinelli L, Kaidar-Person O, Leonardi M, Offersen B, Marazzi F, Rivera S, Tagliaferri L, Tombolini V, Vidali C, Valentini V, Poortmans P The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. Crit. Rev. Oncol. Hematol.. 2019;138. doi:10.1016/j.critrevonc.2019.04.016
Martineau P, Watier H, Turtoi A Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France. MAbs. 2019;11(5):812-825. doi:10.1080/19420862.2019.1612691
Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann B, Christodouleas J, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit. Rev. Oncol. Hematol.. 2019;142. doi:10.1016/j.critrevonc.2019.06.010
Seibold P, Webb A, Aguado-Barrera M, Azria D, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning A, Elliott R, Farcy-Jacquet M-P, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson D, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, De Santis M, Schäfer J, Schnabel T, Sperk E, Symonds R, Stobart H, Taboada-Valladares B, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West C, Chang-Claude J REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138. doi:10.1016/j.radonc.2019.04.034
Lacombe J, Brengues M, Mangé A, Bourgier C, Gourgou S, Pèlegrin A, Ozsahin M, Solassol J, Azria D Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiat Oncol. 2019;14(1):142. doi:10.1186/s13014-019-1351-8
Institut de Recherche en Cancérologie de
